NCT05608395View on ClinicalTrials.gov

11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 4, 2020

Primary Completion Date

June 20, 2024

Study Completion Date

June 20, 2024

Conditions
Glioblastoma Multiforme
Interventions
DRUG

11C-Methionine PET/CT

11C-Methionine PET/CT will be applied in patients in 11C-Methionine PET/CT Arm, based on planning MRI, prior chemo/radiotherapy (2 weeks prior C1D1)

Trial Locations (1)

65653

Masaryk Memorial Cancer Institute, Brno

All Listed Sponsors
lead

Masaryk Memorial Cancer Institute

OTHER

NCT05608395 - 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET) | Biotech Hunter | Biotech Hunter